Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Jun 26;20(1):450.
doi: 10.1186/s12879-020-05175-4.

Global molecular diversity of RSV - the "INFORM RSV" study

Annefleur C Langedijk  1 , Robert Jan Lebbink  2 , Christiana Naaktgeboren  3 , Anouk Evers  2 , Marco C Viveen  2 , Anne Greenough  4   5 , Terho Heikkinen  5   6 , Renato T Stein  7 , Peter Richmond  8 , Federico Martinón-Torres  9 , Marta Nunes  5   10   11 , Mitsuaki Hosoya  12 , Christian Keller  13 , Monika Bauck  14 , Robert Cohen  15 , Jesse Papenburg  16 , Jeffrey Pernica  17 , Marije P Hennus  18 , Hong Jin  19 , David E Tabor  19 , Andrev Tovchigrechko  19 , Alexey Ruzin  19 , Michael E Abram  19 , Deidre Wilkins  19 , Joanne G Wildenbeest  1 , Leyla Kragten-Tabatabaie  5   20 , Frank E J Coenjaerts  2 , Mark T Esser  19 , Louis J Bont  21   22
Affiliations
Multicenter Study

Global molecular diversity of RSV - the "INFORM RSV" study

Annefleur C Langedijk et al. BMC Infect Dis. .

Abstract

Background: Respiratory syncytial virus (RSV) is a global cause of severe respiratory morbidity and mortality in infants. While preventive and therapeutic interventions are being developed, including antivirals, vaccines and monoclonal antibodies, little is known about the global molecular epidemiology of RSV. INFORM is a prospective, multicenter, global clinical study performed by ReSViNET to investigate the worldwide molecular diversity of RSV isolates collected from children less than 5 years of age.

Methods: The INFORM study is performed in 17 countries spanning all inhabited continents and will provide insight into the molecular epidemiology of circulating RSV strains worldwide. Sequencing of > 4000 RSV-positive respiratory samples is planned to detect temporal and geographical molecular patterns on a molecular level over five consecutive years. Additionally, RSV will be cultured from a subset of samples to study the functional implications of specific mutations in the viral genome including viral fitness and susceptibility to different monoclonal antibodies.

Discussion: The sequencing and functional results will be used to investigate susceptibility and resistance to novel RSV preventive or therapeutic interventions. Finally, a repository of globally collected RSV strains and a database of RSV sequences will be created.

Keywords: Molecular epidemiology; Monoclonal antibodies; Next generation sequencing; Respiratory syncytial virus; Temporal and geographical diversity; Vaccines.

PubMed Disclaimer

Conflict of interest statement

FMT and JP are members of the editorial board of BMC Infectious Diseases. MCN has received grant funding from AstraZeneca. JP has received consulting/speaker fees/honoraria from AbbVie, Seegene Canada and Cepheid, and research grant funding outside of the current work from AbbVie, BD Diagnostics, AstraZeneca, Sanofi Pasteur, Hoffmann-La Roche and Janssen Pharmaceutical. LJB has not received personal fees or other personal benefits. UMCU has received funding from Abbvie, AstraZeneca, Janssen, the Bill and Melinda Gates Foundation, Nutricia (Danone) and MeMed Diagnostics. UMCU has received major cash or in kind funding as part of the public private partnership IMI-funded RESCEU project from GSK, Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. UMCU has received major funding by Julius Clinical for participating in the INFORM study sponsored by AstraZeneca. UMCU has received minor funding for participation in trials by Regeneron and Janssen from 2015 to 2017. UMCU received minor funding for consultation and invited lectures by AbbVie, AstraZeneca, Ablynx, Bavaria Nordic, MabXience, Novavax, Pfizer, Janssen. LJB is the founding chairman of the ReSViNET Foundation. Nirsevimab development is jointly funded by AstraZeneca and Sanofi Pasteur.

Figures

Fig. 1
Fig. 1
Countries participating in the INFORM RSV study. Red – Start in 2017; Blue – Start in 2018; Yellow – Start in 2019. The figure was created by ACL using Maptive (https://www.maptive.com)
See this image and copyright information in PMC

References

    1. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–598. doi: 10.1056/NEJMoa0804877. - DOI - PMC - PubMed
    1. Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–958. doi: 10.1016/S0140-6736(17)30938-8. - DOI - PMC - PubMed
    1. Mazur NI, Martinon-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T, Manzoni P, Mejias A, Nair H, Papadopoulos NG, et al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med. 2015;3(11):888–900. doi: 10.1016/S2213-2600(15)00255-6. - DOI - PubMed
    1. Muralidharan A, Li C, Wang L, Li X. Immunopathogenesis associated with formaldehyde-inactivated RSV vaccine in preclinical and clinical studies. Expert Rev Vaccines. 2017;16(4):351–360. doi: 10.1080/14760584.2017.1260452. - DOI - PubMed
    1. Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol. 2008;317:103–123. - PubMed

MeSH terms

Grants and funding